Adocia SA

Adocia S.A. is a clinical-stage biotechnology company dedicated to the research and development of novel formulations of established therapeutic proteins and peptides. Its primary focus is on addressing diabetes and various other metabolic disorders. Central to its work is the exclusive BioChaperone technological platform, engineered to significantly enhance the performance characteristics of therapeutic proteins. Its robust clinical pipeline features several advanced candidates: Insulin-based treatments: Including BioChaperone Lispro U100 and U200, which are ultra-fast-acting versions derived from rapid insulin lispro; BioChaperone Combo, combining long-acting insulin glargine with rapid-acting insulin lispro; and BioChaperone LisPram, which pairs prandial insulin with pramlintide. Hypoglycemia treatment: BioChaperone Glucagon, an aqueous human glucagon solution specifically designed to manage severe low blood sugar episodes. Other: M1Pram, a derivative combining insulin glargine and pramlintide. The preclinical development programs further expand into bi-hormonal products such as BioChaperone AsPram, a combination of rapid insulin aspart and pramlintide, and BioChaperone Glargine Liraglutidea, a co-formulation of insulin glargine and a GLP-1 receptor analogue. Additionally, its preclinical portfolio targets obesity with multi-hormonal products like BioChaperone GluExe (glucagon and exenatide), PramExe (pramlintide and exenatide), and BioChaperone PramGluExe, a tripartite blend of pramlintide, glucagon, and exenatide. Adocia has forged a strategic partnership with Tonghua Dongbao Pharmaceutical Co., Ltd. for the development and market introduction of BioChaperone Lispro and BioChaperone Combo across China, other parts of Asia, and the Middle East. Established in 2005, the company maintains its headquarters in Lyon, France.